Abstract
Abstract
Purpose
This study aimed to develop a transdermal delivery system for fluocinolone acetonide (FLA), a corticosteroid used in treating inflammatory conditions like rheumatoid arthritis (RA), to overcome the limitations of oral administration, such as poor solubility and bioavailability.
Methods
FLA-loaded PEG decorated hyalurosomes (FLA-PHs) were fabricated using ethanol injection, incorporating various Brij® surfactants and different amounts of hyaluronic acid (HA) based on a full factorial design. The impact of independent variables, HA amount (mg) (X1) and Brij type (X2) were inspected for entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP). The optimum FLA-PHs were then incorporated into ε-polycaprolactone (PCL) and cellulose acetate (CA) nanofibers to enhance sustained transdermal delivery (FLA-NFs).
Results
The optimum FLA-PHs exhibited EE% of 83.58 ± 0.69%, PS of 169.00 ± 1.41 nm, and ZP of -22.90 ± 0.14 mV. Morphological assessment of FLA-NFs showed promising results in terms of surface roughness. In a Freund-induced rat model of adjuvant-induced arthritis, transdermal treatment with FLA-NFs significantly improved joint histopathological analyses. Furthermore, it suppressed inflammatory markers such as mTORC1, TNF-α, and NF-κB while upregulating TRIM24 and the anti-inflammatory IL-10.
Conclusion
FLA-NFs present a promising strategy for enhancing the transdermal delivery of FLA for managing RA, offering potential improvements in efficacy and reduced systemic side effects compared to conventional oral administration.
Funder
The Science, Technology & Innovation Funding Authority
Publisher
Springer Science and Business Media LLC